Adobe stock photos - JimObesityLilly’s weight loss pill orforglipron meets primary Phase III endpointEli Lilly, the US market leader in the lucrative diabetes and obesity space, is now challenging its competitor Novo Nordisk in the area of oral GLP-1 receptor agonists. Lilly’s orforglipron has met … more ➔
Calluna Pharma A/SClinical trialsCalluna Pharma starts efficacy test with unique IPF antibodyNorway-based Calluna Pharma A/S has initiated patient recruitment in late August for its Phase II AURORA trial investigating safety and efficacy of CAL101, a monoclonal antibody with unique mode of action … more ➔
BioArctic ABNeurodegenerationNovartis secures US$30m+ licence option from BioArcticFollowing the commercial launch of BioArctic AB’s Alzheimer’s antibody lecanemab, the Swedish company has announced a new deal: it will receive an upfront payment of US$30m, granting the Swiss company … more ➔
Esai PharmaDementiaAlzheimer’s antibody Lecanemab launched in the EUSwedish BioArctic AB’s partner Eisai Pharma has started the European roll-out of their Alzheimer’s antibody lecanemab in Austria that will be followed by the German launch on September 1, 2025. more ➔
EFPIAUS-EU trade conflictUS and EU confirm tariff deal on pharmaceuticals, generics largely exemptThe US and EU have confirmed a trade agreement involving US import tariffs of 15% on prescription medicines. Generics manufacturers will face a maximum tariff of 2.5%. more ➔
MalliaHair growthMallia Aesthetics is about to launch MAL-838Germany’s Mallia Aesthetics GmbH has announced the achievement of key regulatory milestones in preparation for the market launch of its sCD83-based hair growth stimulant, MAL-838, later this year. … more ➔
BioMed XMetabolic DisordersBioMed X and Novo Nordisk collaborate to optimise oral peptide therapeuticsNovo Nordisk has entered a collaboration with research institute BioMed X in an effort to regain market position lost to leading competitors in diabetes and obesity treatment. The partnership is focused … more ➔
Anocca ABImmunoncologyAnocca raises €38.4m to advance TCR-T leads vs. pancreatic cancerSwedish immunoncology specialist Anocca AB has raised SEK440m (€38.36m) ahead of enrolling pancreatic cancer patients in a Phase I umbrella trial evaluating the safety of its T-cell receptor-engineered … more ➔
© EdiMembre/MerckAlternative ProteinMerck and mantro enter the foodtech marketThe laboratory division of Merck KGaA has, in partnership with the German company builder Mantro GmbH, established EdiMembre Inc, a Massachusetts-based company set to deploy Merck’s technologies for … more ➔
adobe stock photos - Tomas RaginaPharmaceutical SupplyTrump delays 250% tariffs on non-U.S. pharmaceuticalsU.S. President Donald Trump’s announcement regarding new tariffs on pharmaceutical goods imported into the United States has been delayed. Despite the President’s threat early last week that a tariff … more ➔
Adobe stock photos - Jim
Calluna Pharma A/S
BioArctic AB
Esai Pharma
EFPIA
Mallia
BioMed X
Anocca AB
© EdiMembre/Merck
adobe stock photos - Tomas Ragina